Craig M Mcdonald

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6596659/publications.pdf

Version: 2024-02-01

198 papers	13,624 citations	25034 57 h-index	24258 110 g-index
206 all docs	206 docs citations	206 times ranked	9001 citing authors

#	Article	IF	Citations
1	Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurology, The, 2010, 9, 77-93.	10.2	1,605
2	Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurology, The, 2010, 9, 177-189.	10.2	975
3	Duchenne Muscular Dystrophy. American Journal of Physical Medicine and Rehabilitation, 1995, 74, S70-S92.	1.4	502
4	Mutations in the early growth response 2 (EGR2) gene are associated with hereditary myelinopathies. Nature Genetics, 1998, 18, 382-384.	21.4	475
5	Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, The, 2017, 390, 1489-1498.	13.7	365
6	Ataluren treatment of patients with nonsense mutation dystrophinopathy. Muscle and Nerve, 2014, 50, 477-487.	2.2	357
7	The 6â€minute walk test as a new outcome measure in Duchenne muscular dystrophy. Muscle and Nerve, 2010, 41, 500-510.	2.2	311
8	Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study. Lancet, The, 2018, 391, 451-461.	13.7	306
9	Natural history of infantileâ€onset spinal muscular atrophy. Annals of Neurology, 2017, 82, 883-891.	5.3	276
10	THE 6â€minute walk test and other endpoints in Duchenne muscular dystrophy: Longitudinal natural history observations over 48 weeks from a multicenter study. Muscle and Nerve, 2013, 48, 343-356.	2.2	258
11	The 6â€minute walk test and other clinical endpoints in duchenne muscular dystrophy: Reliability, concurrent validity, and minimal clinically important differences from a multicenter study. Muscle and Nerve, 2013, 48, 357-368.	2.2	240
12	Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 7153-7158.	7.1	235
13	<scp>LTBP4</scp> genotype predicts age of ambulatory loss in duchenne muscular dystrophy. Annals of Neurology, 2013, 73, 481-488.	5.3	202
14	Development of the <scp>P</scp>erformance of the <scp>U</scp>pper <scp>L</scp>imb module for <scp>D</scp>uchenne muscular dystrophy. Developmental Medicine and Child Neurology, 2013, 55, 1038-1045.	2.1	173
15	Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping. JAMA Neurology, 2020, 77, 982.	9.0	169
16	Physical Activity, Health Impairments, and Disability in Neuromuscular Disease. American Journal of Physical Medicine and Rehabilitation, 2002, 81, S108-S120.	1.4	166
17	The cooperative international neuromuscular research group Duchenne natural history study: Glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and other commonly used clinical trial outcome measures. Muscle and Nerve, 2013, 48, 55-67.	2.2	164
18	Efficacy of idebenone on respiratory function in patients with Duchenne muscular dystrophy not using glucocorticoids (DELOS): a double-blind randomised placebo-controlled phase 3 trial. Lancet, The, 2015, 385, 1748-1757.	13.7	160

#	Article	IF	Citations
19	The cooperative international neuromuscular research group duchenne natural history studyâ€"a longitudinal investigation in the era of glucocorticoid therapy: Design of protocol and the methods used. Muscle and Nerve, 2013, 48, 32-54.	2.2	145
20	The 6â€minute walk test in Duchenne/Becker muscular dystrophy: Longitudinal observations. Muscle and Nerve, 2010, 42, 966-974.	2.2	142
21	Prednisone/prednisolone and deflazacort regimens in the CINRG Duchenne Natural History Study. Neurology, 2015, 85, 1048-1055.	1.1	138
22	Chronic Pain in Persons With Neuromuscular Disease. Archives of Physical Medicine and Rehabilitation, 2005, 86, 1155-1163.	0.9	124
23	DMD genotypes and loss of ambulation in the CINRG Duchenne Natural History Study. Neurology, 2016, 87, 401-409.	1.1	119
24	Genetic modifiers of ambulation in the cooperative international Neuromuscular research group Duchenne natural history study. Annals of Neurology, 2015, 77, 684-696.	5.3	111
25	Facioscapulohumeral Muscular Dystrophy. American Journal of Physical Medicine and Rehabilitation, 1995, 74, S131-S139.	1.4	110
26	Prevention and Management of Limb Contractures in Neuromuscular Diseases. Physical Medicine and Rehabilitation Clinics of North America, 2012, 23, 675-687.	1.3	110
27	Discovery of serum protein biomarkers in the mdx mouse model and cross-species comparison to Duchenne muscular dystrophy patients. Human Molecular Genetics, 2014, 23, 6458-6469.	2.9	106
28	Baseline results of the Neuro<scp>NEXT</scp> spinal muscular atrophy infant biomarker study. Annals of Clinical and Translational Neurology, 2016, 3, 132-145.	3.7	106
29	Nonsense mutation-associated Becker muscular dystrophy: interplay between exon definition and splicing regulatory elements within the DMD gene. Human Mutation, 2011, 32, 299-308.	2.5	103
30	A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy. Neuromuscular Disorders, 2018, 28, 4-15.	0.6	102
31	Spinal Muscular Atrophy. American Journal of Physical Medicine and Rehabilitation, 1995, 74, S150-S159.	1.4	101
32	Chronic Pain in Persons With Myotonic Dystrophy and Facioscapulohumeral Dystrophy. Archives of Physical Medicine and Rehabilitation, 2008, 89, 320-328.	0.9	99
33	Utility of a step activity monitor for the measurement of daily ambulatory activity in children. Archives of Physical Medicine and Rehabilitation, 2005, 86, 793-801.	0.9	97
34	Ambulatory Outcome of Children with Myelomeningocele: Effect of Lowerâ€Extremity Muscle Strength. Developmental Medicine and Child Neurology, 1991, 33, 482-490.	2.1	97
35	Magnetic resonance imaging of denervated muscle: Comparison to electromyography. Muscle and Nerve, 2000, 23, 1431-1434.	2.2	90
36	Metabolic Syndrome in Adolescents With Spinal Cord Dysfunction. Journal of Spinal Cord Medicine, 2007, 30, S127-S139.	1.4	90

#	Article	IF	Citations
37	Use of step activity monitoring for continuous physical activity assessment in boys with Duchenne muscular dystrophy. Archives of Physical Medicine and Rehabilitation, 2005, 86, 802-808.	0.9	89
38	Hereditary Motor and Sensory Neuropathy, Types I and II. American Journal of Physical Medicine and Rehabilitation, 1995, 74, S140-S149.	1.4	88
39	Clinical Approach to the Diagnostic Evaluation of Hereditary and Acquired Neuromuscular Diseases. Physical Medicine and Rehabilitation Clinics of North America, 2012, 23, 495-563.	1.3	83
40	Longitudinal pulmonary function testing outcome measures in Duchenne muscular dystrophy: Long-term natural history with and without glucocorticoids. Neuromuscular Disorders, 2018, 28, 897-909.	0.6	83
41	Urodynamic Findings in the Tethered Spinal Cord Syndrome: Does Surgical Release Improve Bladder Function?. Journal of Urology, 1997, 157, 604-609.	0.4	82
42	Safety and effectiveness of ataluren: comparison of results from the STRIDE Registry and CINRG DMD Natural History Study. Journal of Comparative Effectiveness Research, 2020, 9, 341-360.	1.4	82
43	Motor and cognitive assessment of infants and young boys with Duchenne Muscular Dystrophy: results from the Muscular Dystrophy Association DMD Clinical Research Network. Neuromuscular Disorders, 2013, 23, 529-539.	0.6	79
44	Limb Contractures in Progressive Neuromuscular Disease and the Role of Stretching, Orthotics, and Surgery. Physical Medicine and Rehabilitation Clinics of North America, 1998, 9, 187-211.	1.3	74
45	Quality-of-Life Measures in Children With Neurological Conditions. Neurorehabilitation and Neural Repair, 2012, 26, 36-47.	2.9	72
46	Association Study of Exon Variants in the NF-Î²B and TGFÎ² Pathways Identifies CD40 as a Modifier of Duchenne Muscular Dystrophy. American Journal of Human Genetics, 2016, 99, 1163-1171.	6.2	71
47	Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug. Pharmacological Research, 2018, 136, 140-150.	7.1	69
48	The 6-Minute Walk Test and Person-Reported Outcomes in Boys with Duchenne Muscular Dystrophy and Typically Developing Controls: Longitudinal Comparisons and Clinically-Meaningful Changes Over One Year. PLOS Currents, 2013, 5, .	1.4	69
49	Eteplirsen Treatment Attenuates Respiratory Decline in Ambulatory and Non-Ambulatory Patients with Duchenne Muscular Dystrophy. Journal of Neuromuscular Diseases, 2019, 6, 213-225.	2.6	68
50	Becker??s Muscular Dystrophy. American Journal of Physical Medicine and Rehabilitation, 1995, 74, S93-S103.	1.4	64
51	Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function. Neurology, 2019, 93, e1312-e1323.	1.1	64
52	Pain in Persons With Postpolio Syndrome: Frequency, Intensity, and Impact. Archives of Physical Medicine and Rehabilitation, 2008, 89, 1933-1940.	0.9	63
53	ICU-Acquired Weakness Is Associated With Differences in Clinical Outcomes in Critically Ill Children*. Pediatric Critical Care Medicine, 2016, 17, 53-57.	0.5	62
54	Comparison of indices of traumatic brain injury severity as predictors of neurobehavioral outcome in children. Archives of Physical Medicine and Rehabilitation, 1994, 75, 328-337.	0.9	61

#	Article	IF	Citations
55	Assessment of regional body composition with dualâ€energy Xâ€ray absorptiometry in Duchenne muscular dystrophy: Correlation of regional lean mass and quantitative strength. Muscle and Nerve, 2009, 39, 647-651.	2.2	61
56	Body Mass Index and Body Composition Measures by Dual X-Ray Absorptiometry in Patients Aged 10 to 21 Years With Spinal Cord Injury. Journal of Spinal Cord Medicine, 2007, 30, S97-S104.	1.4	60
57	Classification of the Gait Patterns of Boys With Duchenne Muscular Dystrophy and Their Relationship to Function. Journal of Child Neurology, 2010, 25, 1103-1109.	1.4	60
58	Outcome reliability in nonâ€Ambulatory Boys/Men with duchenne muscular dystrophy. Muscle and Nerve, 2015, 51, 522-532.	2.2	60
59	Limb-Girdle Syndromes. American Journal of Physical Medicine and Rehabilitation, 1995, 74, S117-S130.	1.4	58
60	A phase 3 randomized placebo-controlled trial of tadalafil for Duchenne muscular dystrophy. Neurology, 2017, 89, 1811-1820.	1.1	58
61	Developing standardized corticosteroid treatment for Duchenne muscular dystrophy. Contemporary Clinical Trials, 2017, 58, 34-39.	1.8	56
62	Reliability of Radiographic Parameters in Neuromuscular Scoliosis. Spine, 2007, 32, 691-695.	2.0	55
63	Idebenone reduces respiratory complications in patients with Duchenne muscular dystrophy. Neuromuscular Disorders, 2016, 26, 473-480.	0.6	55
64	The care of patients with Duchenne, Becker, and other muscular dystrophies in the <scp>COVID</scp>â€19 pandemic. Muscle and Nerve, 2020, 62, 41-45.	2.2	54
65	Percent-Predicted 6-Minute Walk Distance in Duchenne Muscular Dystrophy to Account for Maturational Influences. PLOS Currents, 2012, 4, RRN1297.	1.4	54
66	Relationship Between Clinical Outcome Measures and Parent Proxy Reports of Health-Related Quality of Life in Ambulatory Children With Duchenne Muscular Dystrophy. Journal of Child Neurology, 2010, 25, 1130-1144.	1.4	52
67	Body Composition and Water Compartment Measurements in Boys with Duchenne Muscular Dystrophy. American Journal of Physical Medicine and Rehabilitation, 2005, 84, 483-491.	1.4	51
68	Open-Label Evaluation of Eteplirsen in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping: PROMOVI Trial. Journal of Neuromuscular Diseases, 2021, 8, 989-1001.	2.6	50
69	Body Composition and Resting Energy Expenditure in Patients Aged 11 to 21 Years With Spinal Cord Dysfunction Compared to Controls: Comparisons and Relationships Among the Groups. Journal of Spinal Cord Medicine, 2007, 30, S105-S111.	1.4	48
70	Exercise in Neuromuscular Diseases. Physical Medicine and Rehabilitation Clinics of North America, 2012, 23, 653-673.	1.3	48
71	Variable phenotypes associated with mutations in DOK7. Muscle and Nerve, 2008, 37, 448-456.	2.2	46
72	The Natural History of Cardiac and Pulmonary Function Decline in Patients With Duchenne Muscular Dystrophy. Spine, 2011, 36, E1009-E1017.	2.0	46

#	Article	IF	Citations
73	Aerobic Fitness and Upper Extremity Strength in Patients Aged 11 to 21 Years With Spinal Cord Dysfunction as Compared to Ideal Weight and Overweight Controls. Journal of Spinal Cord Medicine, 2007, 30, S88-S96.	1.4	45
74	Feasibility and Reproducibility of Echocardiographic Measures in Children with Muscular Dystrophies. Journal of the American Society of Echocardiography, 2015, 28, 999-1008.	2.8	45
75	Impact of Biopsychosocial Factors on Chronic Pain in Persons With Myotonic and Facioscapulohumeral Muscular Dystrophy. American Journal of Hospice and Palliative Medicine, 2009, 26, 308-319.	1.4	44
76	Effect of Bracing on Paralytic Scoliosis Secondary to Spinal Cord Injury. Journal of Spinal Cord Medicine, 2004, 27, S88-S92.	1.4	43
77	Effect of Different Corticosteroid Dosing Regimens on Clinical Outcomes in Boys With Duchenne Muscular Dystrophy. JAMA - Journal of the American Medical Association, 2022, 327, 1456.	7.4	43
78	Deflazacort versus prednisone/prednisolone for maintaining motor function and delaying loss of ambulation: A post HOC analysis from the ACT DMD trial. Muscle and Nerve, 2018, 58, 639-645.	2.2	42
79	A Randomized, Double-Blind Trial of Lisinopril and Losartan for the Treatment of Cardiomyopathy in Duchenne Muscular Dystrophy. PLOS Currents, 2013, 5, .	1.4	42
80	Efficacy and safety of vamorolone in Duchenne muscular dystrophy:ÂAn 18-month interim analysis of a non-randomized open-label extension study. PLoS Medicine, 2020, 17, e1003222.	8.4	41
81	Meta-analyses of ataluren randomized controlled trials in nonsense mutation Duchenne muscular dystrophy. Journal of Comparative Effectiveness Research, 2020, 9, 973-984.	1.4	41
82	Modifications to the Traditional Description of Neurosegmental Innervation in Myelomeningocele. Developmental Medicine and Child Neurology, 1991, 33, 473-481.	2.1	40
83	Serum pharmacodynamic biomarkers for chronic corticosteroid treatment of children. Scientific Reports, 2016, 6, 31727.	3.3	40
84	Deflazacort vs prednisone treatment for Duchenne muscular dystrophy: A metaâ€analysis of disease progression rates in recent multicenter clinical trials. Muscle and Nerve, 2020, 61, 26-35.	2.2	40
85	Randomized phase 2 trial and open-label extension of domagrozumab in Duchenne muscular dystrophy. Neuromuscular Disorders, 2020, 30, 492-502.	0.6	40
86	How a patient advocacy group developed the first proposed draft guidance document for industry for submission to the U.S. Food and Drug Administration. Orphanet Journal of Rare Diseases, 2015, 10, 82.	2.7	39
87	Measuring clinical effectiveness of medicinal products for the treatment of Duchenne muscular dystrophy. Neuromuscular Disorders, 2015, 25, 96-105.	0.6	39
88	Pulmonary Endpoints in Duchenne Muscular Dystrophy. A Workshop Summary. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 512-519.	5.6	39
89	Clinical phenotypes as predictors of the outcome of skipping around <scp>DMD</scp> exon 45. Annals of Neurology, 2015, 77, 668-674.	5.3	38
90	Mexiletine for muscle cramps in amyotrophic lateral sclerosis: A randomized, doubleâ€blind crossover trial. Muscle and Nerve, 2018, 58, 42-48.	2.2	38

#	Article	IF	Citations
91	Development of a patientâ€reported outcome measure for upper limb function in Duchenne muscular dystrophy: <scp>DMD</scp> Upper Limb <scp>PROM</scp>. Developmental Medicine and Child Neurology, 2017, 59, 224-231.	2.1	37
92	Altered Body Composition Affects Resting Energy Expenditure and Interpretation Of Body Mass Index In Chiloren With Spinal Cord Injury. Journal of Spinal Cord Medicine, 2004, 27, S24-S28.	1.4	36
93	One Year Outcome of Boys With Duchenne Muscular Dystrophy Using the Bayley-III Scales of Infant and Toddler Development. Pediatric Neurology, 2014, 50, 557-563.	2.1	36
94	Characterization of pulmonary function in 10â€“18 year old patients with Duchenne muscular dystrophy. Neuromuscular Disorders, 2017, 27, 307-314.	0.6	36
95	TCTEX1D1 is a genetic modifier of disease progression in Duchenne muscular dystrophy. European Journal of Human Genetics, 2020, 28, 815-825.	2.8	36
96	Genetic modifiers of respiratory function in Duchenne muscular dystrophy. Annals of Clinical and Translational Neurology, 2020, 7, 786-798.	3.7	36
97	Repeated intravenous cardiosphere-derived cell therapy in late-stage Duchenne muscular dystrophy (HOPE-2): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet, The, 2022, 399, 1049-1058.	13.7	36
98	Disease-specific and glucocorticoid-responsive serum biomarkers for Duchenne Muscular Dystrophy. Scientific Reports, 2019, 9, 12167.	3.3	35
99	Long-term data with idebenone on respiratory function outcomes in patients with Duchenne muscular dystrophy. Neuromuscular Disorders, 2020, 30, 5-16.	0.6	33
100	Treatment effect of idebenone on inspiratory function in patients with Duchenne muscular dystrophy. Pediatric Pulmonology, 2017, 52, 508-515.	2.0	32
101	Twiceâ€weekly glucocorticosteroids in infants and young boys with Duchenne muscular dystrophy. Muscle and Nerve, 2019, 59, 650-657.	2.2	32
102	First Regulatory Qualification of a Novel Digital Endpoint in Duchenne Muscular Dystrophy: A Multi-Stakeholder Perspective on the Impact for Patients and for Drug Development in Neuromuscular Diseases. Digital Biomarkers, 2021, 5, 183-190.	4.4	32
103	Spinal Deformity in Progressive Neuromuscular Disease: Natural History and Management. Physical Medicine and Rehabilitation Clinics of North America, 1998, 9, 213-232.	1.3	31
104	Reachable workspace and performance of upper limb (PUL) in duchenne muscular dystrophy. Muscle and Nerve, 2016, 53, 545-554.	2.2	31
105	Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy. JAMA Network Open, 2022, 5, e2144178.	5.9	31
106	Long-Term Functional Efficacy and Safety of Viltolarsen in Patients with Duchenne Muscular Dystrophy. Journal of Neuromuscular Diseases, 2022, 9, 493-501.	2.6	31
107	Change in Life Satisfaction of Adults With Pediatric-Onset Spinal Cord Injury. Archives of Physical Medicine and Rehabilitation, 2008, 89, 2285-2292.	0.9	30
108	Longitudinal community walking activity in Duchenne muscular dystrophy. Muscle and Nerve, 2018, 57, 401-406.	2.2	30

#	Article	IF	Citations
109	(â˜)â€Epicatechin induces mitochondrial biogenesis and markers of muscle regeneration in adults with Becker muscular dystrophy. Muscle and Nerve, 2021, 63, 239-249.	2.2	30
110	Clinical trial readiness in non-ambulatory boys and men with duchenne muscular dystrophy: MDA-DMD network follow-up. Muscle and Nerve, 2016, 54, 681-689.	2.2	29
111	Presynaptic congenital myasthenic syndrome with a homozygous sequence variant in LAMA5 combines myopia, facial tics, and failure of neuromuscular transmission. American Journal of Medical Genetics, Part A, 2017, 173, 2240-2245.	1.2	29
112	Ataluren delays loss of ambulation and respiratory decline in nonsense mutation Duchenne muscular dystrophy patients. Journal of Comparative Effectiveness Research, 2022, 11, 139-155.	1.4	29
113	Preserving Function in Duchenne Dystrophy with Long-Term Pulse Prednisone Therapy. American Journal of Physical Medicine and Rehabilitation, 2000, 79, 455-458.	1.4	28
114	The relationship between regional body composition and quantitative strength in facioscapulohumeral muscular dystrophy (FSHD). Neuromuscular Disorders, 2008, 18, 873-880.	0.6	28
115	Placeboâ€controlled Phase 2 Trial of Drisapersen for Duchenne Muscular Dystrophy. Annals of Clinical and Translational Neurology, 2018, 5, 913-926.	3.7	28
116	Why short stature is beneficial in duchenne muscular dystrophy. Muscle and Nerve, 2013, 48, 336-342.	2.2	27
117	Suitability of external controls for drug evaluation in Duchenne muscular dystrophy. Neurology, 2020, 95, e1381-e1391.	1.1	27
118	Discovery of Metabolic Biomarkers for Duchenne Muscular Dystrophy within a Natural History Study. PLoS ONE, 2016, 11, e0153461.	2.5	26
119	A checklist for clinical trials in rare disease: obstacles and anticipatory actionsâ€"lessons learned from the FOR-DMD trial. Trials, 2018, 19, 291.	1.6	26
120	Management of Pulmonary Complications in Neuromuscular Disease. Physical Medicine and Rehabilitation Clinics of North America, 2012, 23, 829-853.	1.3	25
121	A Combined Prospective and Retrospective Comparison of Long-Term Functional Outcomes Suggests Delayed Loss of Ambulation and Pulmonary Decline with Long-Term Eteplirsen Treatment. Journal of Neuromuscular Diseases, 2022, 9, 39-52.	2.6	24
122	Hip kinetics during gait are clinically meaningful outcomes in young boys with Duchenne muscular dystrophy. Gait and Posture, 2016, 48, 159-164.	1.4	22
123	Comparison of Long-term Ambulatory Function in Patients with Duchenne Muscular Dystrophy Treated with Eteplirsen and Matched Natural History Controls. Journal of Neuromuscular Diseases, 2021, 8, 469-479.	2.6	22
124	Motor scores on the functional independence measure after pediatric spinal cord injury. Spinal Cord, 2009, 47, 213-217.	1.9	21
125	The Validity of Compliance Monitors to Assess Wearing Time of Thoracic-Lumbar-Sacral Orthoses in Children With Spinal Cord Injury. Spine, 2008, 33, 1554-1561.	2.0	19
126	A Prospective Evaluation of the WeeFIM in Patients With Cerebral Palsy Undergoing Orthopaedic Surgery. Journal of Pediatric Orthopaedics, 2006, 26, 542-546.	1.2	17

#	Article	IF	Citations
127	Diagnosis and Clinical Management of Spinal Muscular Atrophy. Physical Medicine and Rehabilitation Clinics of North America, 2008, 19, 661-680.	1.3	17
128	Development of Items Designed to Evaluate Activity Performance and Participation in Children and Adolescents with Spinal Cord Injury. International Journal of Pediatrics (United Kingdom), 2009, 2009, 1-7.	0.8	17
129	Evaluation of Phrenic Nerve and Diaphragm Function with Peripheral Nerve Stimulation and M-Mode Ultrasonography in Potential Pediatric Phrenic Nerve or Diaphragm Pacing Candidates. Physical Medicine and Rehabilitation Clinics of North America, 2015, 26, 133-143.	1.3	17
130	The Direct Cost of Managing a Rare Disease: Assessing Medical and Pharmacy Costs Associated with Duchenne Muscular Dystrophy in the United States. Journal of Managed Care & Specialty Pharmacy, 2017, 23, 633-641.	0.9	17
131	A multinational study on motor function in early-onset FSHD. Neurology, 2018, 90, e1333-e1338.	1.1	17
132	Towards regulatory endorsement of drug development tools to promote the application of model-informed drug development in Duchenne muscular dystrophy. Journal of Pharmacokinetics and Pharmacodynamics, 2019, 46, 441-455.	1.8	17
133	Corticosteroids and duchenne muscular dystrophy: Does earlier treatment really matter?. Muscle and Nerve, 2012, 45, 777-779.	2.2	15
134	Multi-Omics Identifies Circulating miRNA and Protein Biomarkers for Facioscapulohumeral Dystrophy. Journal of Personalized Medicine, 2020, 10, 236.	2.5	15
135	Advances in Pulmonary Care in Duchenne Muscular Dystrophy. US Neurology, 2017, 13, 35.	0.2	15
136	Rehabilitation of Children With Spinal Dysraphism. Neurosurgery Clinics of North America, 1995, 6, 393-412.	1.7	14
137	The <scp>CINRG</scp> Becker Natural History Study: Baseline characteristics. Muscle and Nerve, 2020, 62, 369-376.	2.2	14
138	Evidence-based care in Duchenne muscular dystrophy. Lancet Neurology, The, 2018, 17, 389-391.	10.2	13
139	Conference report on contractures in musculoskeletal and neurological conditions. Muscle and Nerve, 2020, 61, 740-744.	2.2	13
140	A Randomized, Double-Blind, Placebo-Controlled, Global Phase 3 Study of Edasalonexent in Pediatric Patients with Duchenne Muscular Dystrophy: Results of the PolarisDMD Trial. Journal of Neuromuscular Diseases, 2021, 8, 769-784.	2.6	13
141	Real-world and natural history data for drug evaluation in Duchenne muscular dystrophy: suitability of the North Star Ambulatory Assessment for comparisons with external controls. Neuromuscular Disorders, 2022, 32, 271-283.	0.6	13
142	Peripheral Neuropathies of Childhood. Physical Medicine and Rehabilitation Clinics of North America, 2001, 12, 473-490.	1.3	12
143	Pain in Myotonic Muscular Dystrophy, Type 1. Archives of Physical Medicine and Rehabilitation, 2008, 89, 2382.	0.9	11
144	New Clinical End Points in Rehabilitation Medicine: Tools for Measuring Quality of Life. American Journal of Hospice and Palliative Medicine, 2009, 26, 483-492.	1.4	11

#	Article	IF	Citations
145	Regional and Whole-Body Dual-Energy X-Ray Absorptiometry to Guide Treatment and Monitor Disease Progression in Neuromuscular Disease. Physical Medicine and Rehabilitation Clinics of North America, 2012, 23, 67-73.	1.3	11
146	Recruitment & retention program for the NeuroNEXT SMA Biomarker Study: Super Babies for SMA!. Contemporary Clinical Trials Communications, 2018, 11, 113-119.	1.1	11
147	Home-Based Monitoring of Pulmonary Function in Patients with Duchenne Muscular Dystroph. Journal of Neuromuscular Diseases, 2018, 5, 419-430.	2.6	10
148	Can Quantitative Muscle Strength and Functional Motor Ability Differentiate the Influence of Age and Corticosteroids in Ambulatory Boys with Duchenne Muscular Dystrophy?. PLOS Currents, 2016, 8, .	1.4	10
149	Comparing Deflazacort and Prednisone in Duchenne Muscular Dystrophy. Journal of Neuromuscular Diseases, 2022, 9, 463-476.	2.6	10
150	The Minimal Clinical Important Difference (MCID) in Annual Rate of Change of Timed Function Tests in Boys with DMD. Journal of Neuromuscular Diseases, 2021, 8, 939-948.	2.6	9
151	Neurodevelopmental Needs in Young Boys with Duchenne Muscular Dystrophy (DMD): Observations from the Cooperative International Neuromuscular Research Group (CINRG) DMD Natural History Study (DNHS).. PLOS Currents, 2018, 10, .	1.4	9
152	Prednisone and Deflazacort in Duchenne Muscular Dystrophy: Do They Play a Different Role in Child Behavior and Perceived Quality of Life?. PLOS Currents, 2016, 8, .	1.4	9
153	Timed function tests have withstood the test of time as clinically meaningful and responsive endpoints in duchenne muscular dystrophy. Muscle and Nerve, 2018, 58, 614-617.	2.2	8
154	Influence of Î²2 adrenergic receptor genotype on risk of nocturnal ventilation in patients with Duchenne muscular dystrophy. Respiratory Research, 2019, 20, 221.	3.6	8
155	Assessment of Treatment Effect With Multiple Outcomes in 2 Clinical Trials of Patients With Duchenne Muscular Dystrophy. JAMA Network Open, 2020, 3, e1921306.	5.9	8
156	Pediatric Spinal Cord Injury: Evidence-Based Practice and Outcomes. Topics in Spinal Cord Injury Rehabilitation, 2004, 10, 69-78.	1.8	8
157	The Role of the Neuromuscular Medicine and Physiatry Specialists in the Multidisciplinary Management of Neuromuscular Disease. Physical Medicine and Rehabilitation Clinics of North America, 2012, 23, 475-493.	1.3	7
158	Health and fitness in pediatric spinal cord injury: Medical issues and the role of exercise. Journal of Pediatric Rehabilitation Medicine, 2013, 6, 35-44.	0.5	7
159	A presynaptic congenital myasthenic syndrome attributed to a homozygous sequence variant in LAMA5. Annals of the New York Academy of Sciences, 2018, 1413, 119-125.	3.8	7
160	Idebenone as a Novel Therapeutic Approach for Duchenne Muscular Dystrophy. European Neurological Review, 2015, 10, 189.	0.5	7
161	Focal posterior interosseous neuropathy in the presence of hereditary motor and sensory neuropathy, type I. , 1996, 19, 644-648.		6
162	Convexity of Scoliosis Related to Handedness in Identical Twin Boys With Duchenne's Muscular Dystrophy: A Case Report. Archives of Physical Medicine and Rehabilitation, 2008, 89, 2021-2024.	0.9	6

#	Article	IF	Citations
163	Mobility-Assistive Technology in Progressive Neuromuscular Disease. Physical Medicine and Rehabilitation Clinics of North America, 2012, 23, 885-894.	1.3	6
164	Medical management of muscle weakness in Duchenne muscular dystrophy. PLoS ONE, 2020, 15, e0240687.	2.5	6
165	Seven-Year Experience From the National Institute of Neurological Disorders and Strokeâ€“Supported Network for Excellence in Neuroscience Clinical Trials. JAMA Neurology, 2020, 77, 755.	9.0	6
166	Evaluating longitudinal therapy effects via the North Star Ambulatory Assessment. Muscle and Nerve, 2021, 64, 614-619.	2.2	6
167	Meta-analyses of deflazacort versus prednisone/prednisolone in patients with nonsense mutation Duchenne muscular dystrophy. Journal of Comparative Effectiveness Research, 2021, 10, 1337-1347.	1.4	6
168	Quantitative magnetic resonance imaging measures as biomarkers of disease progression in boys with Duchenne muscular dystrophy: a phase 2 trial of domagrozumab. Journal of Neurology, 2022, 269, 4421-4435.	3.6	6
169	PROFILES OF FUNCTIONAL RECOVERY IN FIFTY TRAUMATICALLY BRAIN-INJURED PATIENTS AFTER ACUTE REHABILITATION1. American Journal of Physical Medicine and Rehabilitation, 1997, 76, 213-218.	1.4	5
170	Neuromuscular Disease Management and Rehabilitation, Part II: Specialty Care and Therapeutics. Physical Medicine and Rehabilitation Clinics of North America, 2012, 23, xiii-xvii.	1.3	4
171	Health related quality of life in young, steroid-naÃ¯ve boys with Duchenne muscular dystrophy. Neuromuscular Disorders, 2021, 31, 1161-1168.	0.6	4
172	Rasch Analysis of the Pediatric Quality of Life Inventory 4.0 Generic Core Scales Administered to Patients With Duchenne Muscular Dystrophy. Value in Health, 2021, 24, 1490-1498.	0.3	4
173	Longitudinal changes in cardiac function in Duchenne muscular dystrophy population as measured by magnetic resonance imaging. BMC Cardiovascular Disorders, 2022, 22, .	1.7	4
174	Neuromuscular Disease Management and Rehabilitation, Part I: Diagnostic and Therapy Issues. Physical Medicine and Rehabilitation Clinics of North America, 2012, 23, xvii-xx.	1.3	3
175	Treatment of Spine Deformity in Neuromuscular Diseases. Physical Medicine and Rehabilitation Clinics of North America, 2012, 23, 869-883.	1.3	3
176	Duchenne Regulatory Science Consortium Meeting on Disease Progression Modeling for Duchenne Muscular Dystrophy. PLOS Currents, 2017, 9, .	1.4	3
177	Knee Strength and Ankle Range of Motion Impacts on Timed Function Tests in Duchenne Muscular Dystrophy: In the Era of Glucocorticoids. Journal of Neuromuscular Diseases, 2022, 9, 147-159.	2.6	3
178	Influence of Î²2 adrenergic receptor genotype on longitudinal measures of forced vital capacity in patients with Duchenne muscular dystrophy. Neuromuscular Disorders, 2022, 32, 150-158.	0.6	3
179	Letters to the editor. Muscle and Nerve, 1994, 17, 112-120.	2.2	2
180	Genetic modifiers of upper limb function in Duchenne muscular dystrophy. Journal of Neurology, 2022, 269, 4884-4894.	3.6	2

#	Article	IF	Citations
181	Facilitating orphan drug development: Proceedings of the TREAT-NMD International Conference, December 2015, Washington, DC, USA. Neuromuscular Disorders, 2017, 27, 693-701.	0.6	1
182	Longitudinal changes in energy cost during walking in boys with Duchenne Muscular Dystrophy (DMD). Gait and Posture, 2021, 90, 301-306.	1.4	1
183	The Child with a High Tetraplegic Spinal Cord Injury. Topics in Spinal Cord Injury Rehabilitation, 2005, 10, 19-29.	1.8	1
184	Dedication. Physical Medicine and Rehabilitation Clinics of North America, 2012, 23, xxi-xxii.	1.3	0
185	Predicting age at loss of ambulation in Duchenne muscular dystrophy with deep phenotypic measures. , 2014, , .		0
186	William M. Fowler, Jr, MD, 1926â€2017. PM and R, 2017, 9, 540-541.	1.6	0
187	Myopathic Disorders. , 2021, , 875-915.e3.		0
188	A Longitudinal Study of Quantitative Muscle Strength and Functional Motor Ability in Ambulatory Boys with Duchenne Muscular Dystrophy. Journal of Neuromuscular Diseases, 2022, 9, 321-334.	2.6	0
189	Title is missing!. , 2020, 17, e1003222.		0
190	Title is missing!. , 2020, 17, e1003222.		0
191	Title is missing!. , 2020, 17, e1003222.		0
192	Title is missing!. , 2020, 17, e1003222.		0
193	Title is missing!. , 2020, 17, e1003222.		0
194	Title is missing!. , 2020, 17, e1003222.		0
195	Medical management of muscle weakness in Duchenne muscular dystrophy. , 2020, 15, e0240687.		0
196	Medical management of muscle weakness in Duchenne muscular dystrophy. , 2020, 15, e0240687.		0
197	Medical management of muscle weakness in Duchenne muscular dystrophy. , 2020, 15, e0240687.		0
198	Medical management of muscle weakness in Duchenne muscular dystrophy. , 2020, 15, e0240687.		0